Skip to content
DataLookout
Menu

NCT02171104

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 25 versions: 16 with changes below, 9 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jan 5, 2026 to Jan 5, 2030
    • Eligibility criteria expanded, about 35 words
    • Study completion pushed from Jul 14, 2029 to Jul 14, 2031
    • Secondary endpoints: details revised at 2 of 5 entries
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 100 to confirmed 149
    • Primary completion date changed from estimate of Jul 14, 2026 to Jan 5, 2026
    • Site details revised
    v24
  3. Notable Primary completion date: Jul 14, 2025 to Jul 14, 2026
    • Study completion date: Jul 14, 2028 to Jul 14, 2029
    v23
  4. Notable Primary completion date: Sep 2022 to Jul 14, 2025
    • Study completion date: Dec 2022 to Jul 14, 2028
    v20
  5. Notable Primary completion date: Sep 2021 to Sep 2022
    • Study completion date: Dec 2021 to Dec 2022
    v19
Show 10 earlier versionsHide 10 earlier versions
  1. Minor Site contact updatedv18
  2. Notable Primary completion date: Sep 2020 to Sep 2021
    • Study completion date: Sep 2020 to Dec 2021
    v17
  3. Notable Primary and study completion dates: Sep 2019 to Sep 2020v16
  4. Notable Eligibility criteria revisedv12
  5. Notable Primary endpoints: 1 to 2
    • Eligibility criteria expanded, about 4 words
    • Secondary endpoints: 4 to 5
    v10
  6. Minor Interventions: IMD Preparative Regimen (Drug), Osteopetrosis Haploidentical Only Preparative Regimen (Drug), Osteopetrosis Only Preparative Regimen… to IMD Preparative Regimen (Drug), Osteopetrosis Haploidentical Only Preparative Regimen (Drug), Osteopetrosis Only Preparative Regimen…
    • Study site revised
    • Study arms: 3 to 7
    v9
  7. Notable Eligibility criteria expanded, about 168 wordsv8 Show 5 more changesShow less
    • Start date: Jul 2014 to Jul 10, 2014
    • Interventions: Alpha Lipoic Acid (Drug), Busulfan (Drug), Celecoxib (Drug), Cyclophosphamide (Drug), Cyclosporine A (CSA) (Drug), Fludarabine (Drug)… to IMD Preparative Regimen (Drug), Osteopetrosis Haploidentical Only Preparative Regimen (Drug), Osteopetrosis Only Preparative Regimen…
    • Study description shortened, about 72 words
    • Site contact updated
    • Study arms: 1 to 3
  8. Minor Study arms: 0 to 1
    • Study title shortened, about 2 words
    v5
  9. Minor Interventions: Busulfan (Drug), Cyclosporine A (Drug), Fludarabine monophosphate (Drug), Granulocyte-Colony Stimulating Factor (Drug), Methylprednisolone… to Alpha Lipoic Acid (Drug), Busulfan (Drug), Celecoxib (Drug), Cyclophosphamide (Drug), Cyclosporine A (CSA) (Drug), Fludarabine (Drug)…
    • Secondary endpoints: 3 to 4
    • Study description expanded, about 17 words
    • Site contact updated
    v3
  10. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 2014 to Jul 2014
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percent of subjects who achieve high-level donor hematopoietic engraftment
Timeframe: Day +42 post-transplant

Secondary (4)

Graft-versus-host disease
Transplant-related mortality
Regimen-related toxicity
Post-HSCT changes in disease

Arms and interventions

IMD - Except Haplo-identicalExperimental

Inherited Metabolic Disease (IMD) - Except Haplo-Identical See intervention descriptions.

OP - Except Haplo-IdenticalExperimental

Severe Osteoperosis (OP) - Except Haplo-Identical See intervention descriptions.

OP and IMD -Haplo-Identical OnlyExperimental

Severe Osteopetrosis (OP) and Inhterited Metabolic Disorders (IMD) -Haplo-Identical Only See intervention descriptions.

cALD SR-A (Standard-Risk, Regimen A)Experimental

See intervention descriptions.

cALD SR-B (Standard-Risk, Regimen B)Experimental

See intervention descriptions.

cALD HR-C (High-Risk, Regimen C)Experimental

See intervention descriptions.

cALD HR-D (High-Risk, Regimen D)Experimental

See intervention descriptions.

Biologicals: Stem Cell Transplantation

Drugs: IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen, Osteopetrosis Haploidentical Only Preparative Regimen, cALD SR-A (Standard-Risk, Regimen A), cALD SR-B (Standard-Risk, Regimen B), cALD HR-D (High-Risk, Regimen C), cALD HR-D (High-Risk, Regimen D)

Sites

1 site in 1 country

  • Masonic Cancer Center, University of MinnesotaMinneapolis, Minnesota, United States